Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case

Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case–control study

Published:2022-04-06 Issue:11 Volume:42 Page:1939-1946
ISSN:1437-160X
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Yoshimura Masaru^ORCID,Fujieda Yuichiro^ORCID,Sugawara Masanari^ORCID,Kono Michihito^ORCID,Kato Masaru^ORCID,Yokota Isao^ORCID,Amengual Olga^ORCID,Ito Yoichi M.^ORCID,Atsumi Tatsuya^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s00296-022-05121-4.pdf

Reference35 articles.

1. Crous-Bou M, Harrington LB, Kabrhel C (2016) Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemost 42(8):808–820. https://doi.org/10.1055/s-0036-1592333

2. Khan F, Tritschler T, Kahn SR, Rodger MA (2021) Venous thromboembolism. Lancet 398(10294):64–77. https://doi.org/10.1016/S0140-6736(20)32658-1

3. Bisoendial RJ, Levi M, Tak PP, Stroes ES (2010) The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events. Semin Thromb Hemost 36(4):452–457. https://doi.org/10.1055/s-0030-1254054

4. Borensztajn KS, von der Thusen JH, Spek CA (2011) The role of coagulation in chronic inflammatory disorders: a jack of all trades. Curr Pharm Des 17(1):9–16. https://doi.org/10.2174/138161211795049813

5. Nieuwdorp M, Stroes ES, Meijers JC, Buller H (2005) Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 5(2):155–159. https://doi.org/10.1016/j.coph.2004.10.003

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review and meta‐analysis of the association between the D‐dimer and rheumatic diseases;Immunity, Inflammation and Disease;2024-07

2. Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors;JCR: Journal of Clinical Rheumatology;2024-06-17

3. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients;Arthritis & Rheumatology;2024-04-19

4. Rheumatoide Arthritis – Einordnung der neuen Sicherheitswarnungen für JAK-Inhibitoren;DMW - Deutsche Medizinische Wochenschrift;2024-02-27

5. Neues zu Weichteilsarkomen;DMW - Deutsche Medizinische Wochenschrift;2024-02-27